Checkpoint kinase 1 inhibitor? plus ?low-dose hydroxyurea efficiently kills BRAF inhibitor- and immune checkpoint inhibitor-resistant melanomas

Article Dermatology

IFN-y Signaling Sensitizes Melanoma Cells to BH3 Mimetics

Zizhen Ming et al.

Summary: Immunotherapy targeting PD-1 and/or CTLA4 can lead to durable responses in some melanoma patients. However, treatment resistance and lack of response are common. This study identifies a vulnerability in melanoma driven by immune cell activity, providing potential strategies for combination therapies.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

Add to Collection

Review Oncology

Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis

Konstantinos Christofyllakis et al.

Summary: This study evaluated the efficacy and tolerability of adjuvant therapy options in completely resected high-risk malignant melanoma patients. Results showed that nivolumab/ipilimumab had the highest benefit in stage IV melanoma, while dabrafenib/trametinib performed well in stage III BRAF-mutant melanoma. The presence of a BRAF mutation had a favorable impact on RFS, and patient age did not influence treatment outcomes.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression

Martina Proctor et al.

Summary: Targeted therapies focusing on replication stress have shown promising results in selectively killing tumors while also enhancing immune response for effective tumor control. Despite some challenges in clinical translation, these therapies offer potential for improving cancer treatment outcomes.

CANCERS (2021)

Add to Collection

Review Biochemistry & Molecular Biology